You are here

Developing the Next Generation PD-L1 Assays Using Precision Mass Spectrometry

Status: 
Active
Competition: 
Genomic Applications Partnership Program
Sector: 
Health
Genome Centre(s):
Génome Québec
Project Leader(s):
Christoph Borchers and Alan Spatz (Lady Davis Institute, Jewish General Hospital)
Receptor Leader(s):
Claude Leduc (MRM Proteomics Inc.)
GE3LS: 
No
Fiscal Year Project Launched: 
2019-2020
Project Description: 

Lung cancer accounts for 14% of all diagnosed cancers in Canada from which 80% of patients will be tested for programmed cell death protein 1 (PD-L1) through the course of the disease. This project aims to develop PD-L1 Mass Spectrometry (MS)-based assays for use in immune-oncology. The Receptor, MRM Proteomics, in partnership with the academic leaders will develop two alternative analytical pipelines based on multiple reaction monitoring (MRM, for research purposes) and immuno MALDI (iMALDI technology, suitable for clinical diagnostics). The anticipated revenues for MRMP’s new PD-L1 kit is projected as $3.5 million over the first five years post project and with the addition of the iMALDI technology to 20% of the PD-L1 test kits would generate more than $250 million.